interferon beta 1a therapy

http://health.usnews.com/health-news/news/articles/2012/04/19/early-use-of-ms-drug-may-cut-likelihood-of-progression THURSDAY, April 19 (HealthDay News) -- A new three-year study finds that a multiple sclerosis drug is more likely to prevent patients from progressing to a definite form of MS if it's given early in patients who appear to be ill. The drug, a form of interferon called "interferon beta-1a," is not available in the United States.

The standard therapy options include intravenous immunoglobulin and plasmapharesis, corticosteroids, azathioprine, cyclophosphamide, etanercept, mycophenolate mofetil, interferon alpha 2a and tacrolimus. Current ones are interferon beta 1a, rituximab, and high dose cyclophosphamide. Your neurologist needs to apprise you of the long-term side effects since prolonged therapy are required. Botox shots are not known to be used in therapy.

Are you facing a decision about choosing a med? Of the four approved for use in MS, three are Interferons (specifically beta-1a) and one, Copaxone is not. They are all about equally effective in RRMS. Do you have concerns about being on an interferon?

I have been treating my multiple sclerosis (MS) with avonnex (interferon beta-1a) for the past ten years. I have had four severe flare ups, three in the first four years and one in the last six months. which I needed physical therapy to walk again. In 2003 I was diagnosed with Hep C, it has recent progressed to stage 3 fibrosis. I have a reason to believe that my MS treatment is damaging my liver and causing my fibrosis to advance.

Just a quick poll to see how many cirrhotics have done triple therapy and what their experience was?

Trial 108 (ADVANCE) Trial 108 was a randomized, double-blind, parallel-group, placebo-controlled trial conducted in treatment-naïve subjects (had received no prior therapy for HCV, including interferon or pegylated interferon monotherapy). Incivek was given for the first 8 weeks of treatment (T8/PR regimen) or the first 12 weeks of treatment (T12/PR regimen) in combination with Peg-IFN-alfa-2a/RBV for either 24 or 48 weeks.

genotype 1a minimally requires 48 weeks of interferon/ribavirin therapy, and patients will respond successfully to the therapy in 45-50% of cases. Have you recently been diagnosed?

Earlier Phase 2 studies showed that treatment with alemtuzumab reduced the accumulation of disability and the frequency of relapses in people with early relapsing-remitting MS, compared to Rebif® (interferon-beta-1a-rebif/index.aspx, interferon beta-1a, EMD Serono, Inc. and Pfizer, Inc.). (New England Journal of Medicine 2008 359;17:30-45) Rebif is a registered trademark of EMD Serono, Inc. and Pfizer, Inc. http://www.nationalmssociety.org/news/news-detail/index.aspx?

as expected, only 20% of null responders in the dual-therapy arm and none in the triple-therapy arm had this favorable pattern.' P.S. I am a prior null-responder and became undetectable by week 2 with only GS-7977 + Ribavirin. I didn't have the addition of GS-5885.

In this post-hoc study, MRI scans were analyzed from patients with relapsing MS participating in a placebo-controlled trial of interferon beta-1a. The brain parenchymal fraction, defined as the ratio of brain parenchymal volume to the total volume within the brain surface contour, was used to measure whole brain atrophy. The relationship between disease features and brain atrophy and effect of interferon beta-1a were determined.

As can-do says a repeated blood tests will declare itself on way or another. Either it was a false positive or the viral load will rise quickly as the virus replicates quickly when it is not suppressed by the therapy ("viral breakthrough").

I have been treated previously with A) Interferon 1995 B) Interferon (non peg) and Ribaviron 1998. Levels dropped to normal second time around but quit at week 10 as levels began going up and the side effects were too much. Now I am about to start Peg Interferon, Rib and Incivek. Wondering if I will notice much difference in the side effects. And, because I initially responded well last time, does that indicate a good chance of success this time ?

was FDA approved in combination with peginterferon alfa and ribavirin to treat HCV genotype 1, adults, with compensated liver disease, including cirrhosis, who are treatment-naïve or who have failed previous interferon therapy (pegylated or non‑pegylated) with ribavirin. Although, simeprevir appears to be slightly more effective than the standard of care, curing 80 percent of treatment-naïve patients, and easier to take, there are some drawbacks.

Might I ask what was your baseline viral load? Did you have ≥ 2 log 10 drop in viral load at week 12? I am a Geno 1a and I had to stop dual therapy (Pegasys & Ribavarin) at week 19 since there was no change in my VL after week 12. I wanted to hang in there in hope something would happen but in retrospect I should have followed the stopping rule. We Geno 1s don't have a good track record with dual therapy.

When I went on Incivek I did so thinking the cure rate was 80+ percent, but found out all along my chances were really only 30 percent. I am a genotype 1a, I relapsed from triple therapy with Incivek after 48 weeks. Not sure what my liver status is right now, getting a biopsy in January. Thanks for anything you can find.

) Pharmacokinetics The pharmacokinetics of Rebif® (interferon beta-1a) in people with multiple sclerosis have not been evaluated. In healthy volunteer subjects, a single subcutaneous (sc) injection of 60 mcg of Rebif® (liquid formulation) resulted in a peak serum concentration (Cmax) of 5.1 ± 1.7 IU/mL (mean ± SD), with a median time of peak serum concentration (Tmax) of 16 hours.

I am no expert, but since three of the CRAB drugs are interferon beta (either 1a or 1b), they should all have the similar benefits/risks.

I am 1a, treatment experienced with Victrelis/interferon/Ribavirin. I was on the 48 week regime due to F3/4 status. I never hit undetected...got to VL of 16, and had to stop at week 24 in September 2012. My doctor and I chose the Sovaldi +SOC this go around as my MD was concerned about mutation from the Olysio. One week post treatment today. Hope it worked...MD appt 8/25. One revolution at a time. Best wishes to all!

In the case of a virus with a low barrier to resistance development, such as HCV subtype 1a, the strength of the innate response coupled with antiviral therapy becomes critical. This might be reflected in an enhanced ability to respond to locally produced interferon and to minimize breakthrough of resistant viral variants.

Please talk to your doctor about testing for genotype 1a Q80K and using a different therapy when genotype 1a Q80K is present. It is not known if OLYSIO™ is safe and effective in children under 18 years of age.

Well, I was on Triple Therapy with Victrelis, so there is a 4 week "lead in" with just the Interferon and Ribavirin, so after 4 weeks of just that "soc"(standard of care) I was Undetected. I then went on to do an additional 24 weeks on the three meds then: Victrelis, Inf., and Riba. So it was actually a 28 week Triple Treatment for me.

I am slated to start triple therapy in Feb. 2012. Does anyone have any experience or knowledge regarding peg interferon and pancreatitis. I appreciate any response..... and thank you in advance.

Interferon beta 1a therapy

Common Questions and Answers about Interferon beta 1a therapy

rebif